✦ LIBER ✦

Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes

✍ Scribed by Walter Verbeek; Bernhard Wörmann; Peter Koch; Carl Aul; Hans-Fokke Hinrichs; Leopold Balleisen; Jacob M. Rowe; John Bennett; Detlef Haase; Christa Fonatsch; Anton Heinecke; Thomas Büchner; Wolfgang Hiddemann

Book ID: 106124814
Publisher: Springer-Verlag
Year: 1999
Tongue: English
Weight: 99 KB
Volume: 125
Category: Article
ISSN: 1432-1335
DOI: 10.1007/s004320050288

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Low-dose cytosine arabinoside (LD-AraC)

Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group

✍ Zwierzina, H; Suciu, S; Loeffler-Ragg, J; Neuwirtova, R; Fenaux, P; Beksac, M; H 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 116 KB